AI news impact · US stocks
Moderna, Inc. (MRNA) news impact
On 2026-11-13 Wave Radar's AI rated the news on Moderna, Inc. as neutral (impact score +20%).
Moderna raised its 2026 revenue growth forecast to 15%–25% and advanced its Merck-partnered individualized cancer therapy toward a 2027 launch, though 2027 cost concerns limited gains.
- Direction
- Neutral
- Impact score
- +20%
- Confidence
- 85%
- Headlines read
- 4
- Date
- 2026-11-13
AI assessment
Upgraded revenue guidance for 2026 and progress in individualized cancer vaccines provide fundamental support, partially offset by 2027 cost projections.
Sector impact
Supports sentiment across oncology and mRNA biotechnology developers while keeping focus on cost containment.
Headlines the AI read
- Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls Yahoo Finance/MRNA · 2026-11-13
- Moderna Targets 2027 Cancer Therapy Launch, Raises 2026 Revenue Growth Outlook Yahoo Finance/MRNA · 2026-11-12
- MRNA Stock Up 3% Since Q3 Earnings Release: How to Play the Stock? Yahoo Finance/MRNA · 2026-11-12
- Moderna Raises 2026 Revenue Growth Forecast to 15%–25% and Reports Progress in Cancer Vaccine Development Yahoo Finance/MRNA · 2026-11-12
Rating history
One rating per trading day the stock was covered.
More on Moderna, Inc.
How the rating works
After each close Wave Radar collects the day's headlines and filings for a stock and asks an AI model what they mean for it. The rating is one of five levels from major negative to major positive; the impact score runs from −100% to +100%, and a rating built on a single uncorroborated source is capped. It describes the news, not the price outlook.
Figures are generated automatically from Wave Radar's published market data and refresh after each market close.